The American Journal of Managed Care19h
Rare Blood Disease Innovations Address Unmet Needs, According to ASH Data
Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...
The Pharma Letter2d
Sarclisa data could reshape myeloma treatment landscape
Sanofi’s Sarclisa shows significant Phase III results for multiple myeloma, delivering deeper and longer-lasting responses in ...
PharmiWeb2d
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...
Sanofi says Sarclisa combos showed benefits in multiple myeloma patients
Sanofi (SNY) says new data from three oral presentations demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly ...
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program
Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today ...